Navigation Links
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Date:8/19/2007

Multi-Center International Study to Determine the Efficacy of LBH589 in

Patients with Relapsed or Refractory Multiple Myeloma

NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID(R)), and dexamethasone in collaboration with Keryx Biopharmaceuticals.

"Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this important clinical program," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is facilitating demonstrate the importance of novel collaborations in bringing new treatments to patients."

Named ALPHA-MM, this trial is a single arm, open label, multi-center global study that will enroll 144 patients in the United States, Canada, and Europe. MMRC Member Institutions that will enroll patients are Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory University, Hackensack University Medical Center, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or r
'/>"/>

SOURCE The Multiple Myeloma Research Consortium

Copyright©2007 PR Newswire.

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... More than 3,500 attendees from top pharmaceutical, fine chemical ... conference, which includes on-site education sessions, daily networking events ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ... need for oxygen when air is thin," states Dr Barnes. She ...
(Date:1/14/2014)... WASHINGTON, New York , January 14, ... http://www.equashield.com ), the leading provider of Closed System Transfer Devices (CSTD) ... has achieved 60% year-over-year sales growth for ... Equashield,s closed systems reduce the risk of ... other medical professionals who prepare and administer ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... IPSWICH, Mass., April 12, 2011 New England Biolabs ... of reagents for life science research, announces that it ... the Netherlands, and Imperial Life Sciences (ILS), based in ... BIOKE, a Cell Signaling Technology (CST) Europe ...
... leading EchoStim® Echogenic Insulated needle has been improved. ... Blocks (PNBs) using nerve stimulation and ultrasound guidance ... has more, brighter, easier to see reflectors, which ... the benefits of using both nerve block techniques ...
Cached Medicine Technology:New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... WASHINGTON, May 12 A new report from ... medications for a variety of diseases often are ... and Asian Americans. This comprehensive review of studies ... Origins and Strategies for Addressing Ethnic and ...
... the personal injury attorney firm in Manhattan, is standing up against insurance ... ... 2009 -- New York personal injury lawyers can have a ... business. When it comes to frivolous lawsuits, these monsters want the public ...
... President of CanReg Inc., is pleased to announce that ... Executive Advisory Strategist to assist client firms with their ... with small to medium sized public and private biotechnology ... been on directing and managing regulatory affairs, most recently ...
... other strains of influenza, CDC says , , TUESDAY, May 12 ... seeing some complications among pregnant women as the swine flu ... at higher risk of complications of influenza, whether it,s the ... seeing some severe complications in women with this year,s novel ...
... The Pennsylvania Department of Aging and the Office of ... Council that will advise on new policies and procedures to ... citizens and those with disabilities prefer to live independently and ... so we want to make sure that the services we ...
... (Nasdaq: VOLC ), a leader in the ... and treatment of coronary and peripheral artery disease, said ... Annual JMP Securities Research Conference on Monday, May 18.The ... at 3:00 p.m., Pacific Daylight Time (6:00 p.m., Eastern ...
Cached Medicine News:Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 2Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 3Health News:Report Reveals Disparities in Pharmaceutical Treatment for Minority Patients 4Health News:Manhattan Personal Injury Attorney Blames Insurance Industry For Negative Perception Of Civil Justice System 2Health News:Swine Flu May Pose Problems for Pregnant Women 2Health News:Swine Flu May Pose Problems for Pregnant Women 3Health News:Swine Flu May Pose Problems for Pregnant Women 4Health News:Swine Flu May Pose Problems for Pregnant Women 5Health News:Swine Flu May Pose Problems for Pregnant Women 6Health News:Swine Flu May Pose Problems for Pregnant Women 7Health News:Swine Flu May Pose Problems for Pregnant Women 8Health News:Swine Flu May Pose Problems for Pregnant Women 9Health News:Pennsylvania Council Formed to Advise on Improving Services to Older Adults, People with Disabilities 2Health News:Volcano Corporation Presentation at JMP Conference to be Webcast 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: